AstraZeneca plc Receives “Underweight” Rating from JPMorgan Chase & Co. (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “underweight” rating restated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday. They currently have a GBX 3,700 ($63.02) price objective on the stock. JPMorgan Chase & Co.’s target price points to a potential downside of 16.26% from the company’s current price.
AstraZeneca plc (LON:AZN) opened at 4409.50 on Thursday. AstraZeneca plc has a 52 week low of GBX 3086.50 and a 52 week high of GBX 5750.00. The stock’s 50-day moving average is GBX 4389.50 and its 200-day moving average is GBX 4059.10. The company’s market cap is £55.604 billion.
A number of other firms have also recently commented on AZN. Analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 3,950 ($67.28) price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca plc in a research note on Thursday, June 26th. They now have a GBX 4,400 ($74.94) price target on the stock. Finally, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, June 20th. Seven research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of GBX 3,990.48 ($67.97).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.